From the Web of Science Core Collection database, publication data was downloaded. Using CiteSpace and VOSviewer for a bibliometric analysis, the collaborative efforts, co-occurrence patterns, and research hotspots among different countries/regions, institutions, and authors were examined within the field.
A database search yielded 3531 English articles published between 2012 and 2021. A noteworthy increase in the output of publications was evident from the year 2012. Lab Automation Significantly high article production characterized China and the United States, with each exceeding 1000 articles. A significant contribution to the publication record came from the Chinese Academy of Sciences, resulting in 153 publications (n = 153).
and
Tumor ablation and immunity may be of significant interest, as demonstrated by 14 and 13 publications. From the list of the ten most frequently cited authors,
Topping the list with 284 citations was the first-ranked entry, closely followed by…
In the current research, 270 citations were examined.
A compilation of 246 sentences, each distinctly phrased. Photothermal therapy and immune checkpoint blockade were highlighted as pivotal research areas based on the co-occurrence and cluster analysis findings.
Over the past ten years, the field of tumor ablation domain immunity within its neighborhood has received heightened consideration. The leading research themes in this field currently involve the exploration of immunological mechanisms in photothermal therapy to improve its therapeutic outcome, and the collaborative approach of using ablation therapy with immune checkpoint inhibitor treatments.
Over the past ten years, the field of tumor ablation domain immunity has garnered increasing attention. Key research areas in this field are currently dedicated to uncovering the immunological mechanisms underlying photothermal therapy to increase its effectiveness, and to merging ablation therapy with immune checkpoint inhibitor treatment strategies.
The occurrence of rare inherited syndromes, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP), is linked to biallelic pathogenic variants.
and heterozygous variants, pathogenic, in
A list of sentences is offered, respectively, by this JSON schema. Clinical diagnosis of APECED and POIKTMP is predicated on the development of a minimum of two or more characteristic disease manifestations, defining their respective syndromes. The patient case we present examines the overlapping and distinct clinical, radiographic, and histological traits of APECED and POIKTMP, focusing on his response to azathioprine treatment for the POIKTMP-related hepatitis, myositis, and pneumonitis.
Following informed consent and enrollment in IRB-approved protocols (NCT01386437, NCT03206099), the patient was subjected to a comprehensive clinical evaluation at the NIH Clinical Center, including exome sequencing, copy number variation analysis, autoantibody surveys, peripheral blood immunophenotyping, and salivary cytokine analysis.
Evaluation and reporting of a 9-year-old boy presenting to the NIH Clinical Center with an APECED-like clinical picture, including the classic APECED dyad, namely chronic mucocutaneous candidiasis and hypoparathyroidism, are detailed in this case report. Upon investigation, he demonstrated the clinical diagnostic criteria for POIKTMP, including poikiloderma, tendon contractures, myopathy, and pneumonitis; and exome sequencing analysis was performed.
The presence of a heterozygous pathogenic variant, c.1292T>C, was detected in the sample.
Still, no detrimental single-nucleotide polymorphisms or copy-number changes were found.
.
This report details the existing genetic, clinical, autoantibody, immunological, and treatment-response data for POIKTMP.
This report offers a broader perspective on the genetic, clinical, autoantibody, immunological, and treatment response information surrounding POIKTMP by expanding upon previously available data.
Residents living near sea level often experience altitude sickness while hiking or exploring elevations exceeding approximately 2500 meters, a condition linked to hypobaric hypoxia (HH) prevalent in these high-altitude locales. The induction of maladaptive metabolic reprogramming in macrophages by HH is linked to cardiac inflammation in both ventricles, stimulating amplified pro-inflammatory responses and consequently causing myocarditis, fibrotic remodeling, arrhythmias, heart failure, and sudden cardiac deaths. Extensive research has demonstrated the cardioprotective benefits of salidroside or altitude preconditioning (AP) prior to high-altitude excursions. Nevertheless, both therapeutic approaches face geographical constraints, rendering them inaccessible or unavailable to the vast majority of the population. Occlusion preconditioning (OP) is extensively documented to provoke endogenous cardioprotective cascades, successfully preventing hypoxia-induced cardiomyocyte damage and diminishing myocardial harm. To explore OP as an alternative therapeutic approach for preventing HH-induced myocarditis, remodeling, and arrhythmias, we posited its convenient applicability across various settings.
In mice, six daily cycles of hindlimb occlusions (5 minutes at 200 mmHg) and reperfusion (5 minutes at 0 mmHg) were performed on alternate limbs for seven days, after which cardiac electrical activity, immune responses, myocardial structural changes, metabolic equilibrium, oxidative stress reactions, and behavioral patterns were assessed both prior to and after high-height exposure. Each participant underwent cardiopulmonary exercise testing (CPET) before and after 6 days of intervention, during which time they experienced 6 cycles daily of 5 minutes occlusion at 130% of systolic pressure followed by 5 minutes reperfusion at 0 mmHg, targeting the alternate upper limb.
In evaluating the consequences of OP and AP interventions, a pattern emerged. Similar to AP, OP retained cardiac electrical activity, diminished maladaptive myocardial remodeling, prompted adaptive immune responses, and preserved metabolic homeostasis in the heart. Furthermore, OP amplified antioxidant defenses and protected against HH-induced anxiety-related behaviors. In addition, OP augmented respiratory efficiency, oxygen-carrying capability, metabolic stability, and stamina in humans.
This research underscores OP's potential as a significant alternative therapeutic agent for preventing hypoxia-induced myocarditis, cardiac remodeling, arrhythmias, and cardiometabolic disorders, possibly alleviating the development of other inflammatory, metabolic, and oxidative stress-related illnesses.
The observed effects of OP indicate a potent alternative therapy for averting hypoxia-induced myocarditis, cardiac remodeling, arrhythmias, and cardiometabolic disorders, and potentially ameliorating other inflammatory, metabolic, and oxidative stress-related diseases.
The potent anti-inflammatory and regenerative functions of mesenchymal stromal cells (MSCs) and their secreted extracellular vesicles (EVs) in the context of inflammation and tissue damage make them a compelling tool for cellular therapy. The current study investigated the inducible immunoregulatory properties of mesenchymal stem cells and their secreted vesicles upon stimulation with a variety of cytokine combinations. MSCs treated with IFN-, TNF-, and IL-1 exhibited an increase in PD-1 ligand expression, signifying their critical involvement in immunomodulation. MSCs and MSC-EVs subjected to priming exhibited a marked increase in their capacity to suppress activated T cells and induce regulatory T cells in comparison to non-stimulated cells. This augmented effect was contingent on PD-1 signaling. Primed MSC-derived EVs exhibited a significant impact, reducing the clinical score and prolonging the survival of mice within a graft-versus-host disease model. In vitro and in vivo, these effects could be counteracted by adding neutralizing antibodies against PD-L1 and PD-L2 to both the mesenchymal stem cells and their extracellular vesicles. Our findings, in their entirety, portray a priming approach that elevates the immunoregulatory function of mesenchymal stem cells and their extracellular vesicles. Butyzamide datasheet The concept of cellular or exosome-based MSC therapies also presents new avenues to improve their clinical usability and effectiveness.
The natural protein content of human urine is substantial, simplifying the process of translating these proteins into biopharmaceutical products. Utilizing both this goldmine and ligand-affinity-chromatography (LAC) purification, researchers achieved substantial success in isolating the compounds. LAC's specificity, efficiency, simplicity, and essential nature in the identification of both predictable and unpredictable proteins make it an exceptional separation technique over alternatives. Recombinant cytokines and monoclonal antibodies (mAbs) in abundance expedited the decisive triumph. Incidental genetic findings My 35-year global quest for the Type I IFN receptor (IFNAR2) culminated in an approach that significantly advanced our knowledge of this IFN's signal transduction pathways. By employing TNF, IFN, and IL-6 as bait, the isolation of their corresponding soluble receptors was achieved. Subsequently, N-terminal amino acid sequences of these isolated proteins were instrumental in cloning their cell surface counterparts. Heparanase, IL-18, and IL-32, as lures, revealed corresponding, unexpected proteins: IL-18 Binding Protein (IL-18BP), Proteinase 3 (PR3), and the hormone Resistin. In the realm of Multiple Sclerosis treatment, IFN demonstrated substantial benefits, with Rebif standing as a prime example. TNF mAbs, a form of therapy, were effectively translated from Remicade for use in treating Crohn's disease. For Rheumatoid Arthritis, Enbrel's active ingredient is based on TBPII. Both are substantial commercial achievements, making a huge impact. Tadekinig alfa, a recombinant IL-18 binding protein, is the subject of phase III clinical studies, investigating its potential in treating inflammatory and autoimmune diseases. Children with NLRC4 or XIAP mutations, receiving Tadekinig alfa for seven continuous years with compassion, experienced life-saving outcomes, demonstrating the efficacy of tailored medical approaches.